IS DRUNK AND HAS LOST HER BROOMSTICK
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
on 7/15
Electric-car startup Faraday Future is already in expansion mode
http://goo.gl/LgLKCG
Electric cars make 'economic sense'
http://goo.gl/F6B78X
Daimler to unveil long-distance electric car in October
http://goo.gl/EqIMfG
Perfect storm of factors speeding electric vehicle development
https://goo.gl/H0uNve
The rapid growth of electric cars worldwide, in 4 charts
http://goo.gl/zSrRl7
You are exactly right...
Musk Expects Apple to Roll Out Electric Car by 2020
http://goo.gl/gsblwB
I TALKED WITH BRIAN A WEEK OR SO AGO..Had NO PROBLEM REACHING HIM
Electric-car intender Faraday Future wants 2nd factory, in California this time
http://goo.gl/Pu9CYJ
Deployment Miracle Puts Electric Vehicles On Track To Save Livable Climate
http://goo.gl/AzhoYQ
Electric cars will be part of Hyundai's Genesis lineup
http://goo.gl/0BFISF
Nice to hear from you..keep your eyes on us and hope you post some more..love to hear what your favorites are...
What does 50 days have to do with anything...
I cleaned out the .0038 lets get the .0039
Put your bids in @ .0023 I am bidding for 300k there if we get some big size ti could get hit
From CCGI 3rd Q 10
On September 9, 2015, the United States Court of Appeals for the Seventh Circuit of Chicago, Illinois affirmed the ruling of the United States District Court for the Northern District of Illinois in the matter of JNS Power & Control Systems, Inc. v. 350 Green, LLC in favor of JNS, which affirmed the sale of certain assets by 350 Green to JNS and the assumption of certain 350 Green liabilities by JNS. On April 7, 2016, JNS amended the complaint to add CCGI alleging lost revenues from the chargers, among other matters, caused by the defendants. Plaintiff also seeks indemnity for its costs in connection with enforcing the Asset Purchase Agreement in courts in New York and Chicago. CCGI and 350 Green must respond to the amended complaint on or before June 20, 2016.
exactly
I know that..I agreed with you did you read my post I said you were 100% right..
She is 100% right..
As do I...
I will be there
Lets total all holders up
How many you hold PB
Holding my 18 million for .02 plus....
Been waiting a long time for this news..could be beyond big...
Please a tweet for JNSH
Link to Forbes piece..
http://goo.gl/rpKPTj
New products and FDA approvals. These are two key factors investors should focus on before putting their trust and money in a biopharma or biotech company, particularly the young ones. And some savvy investors may have spotted such an opportunity with OPKO Health, Inc. (OPK). a diversified drug and medical diagnostics company, with its own significant proprietary drug portfolio.
The reason: One of OPKO’s major drugs, Rayaldee, an oral vitamin D treatment aimed at people suffering from chronic kidney disease, is expected to be approved by the Food and Drug Administration by the end of March.
The expectation for the approval is based on OPKO’s obtaining recently a PDUFA (Prescription Drug User Fee Act) dated March 29, 2016. The PDUFA date represents the deadline for the FDA to approve a new drug. As a result, Wall Street analysts have been effusive in their positive comments about OPKO and its stock. Chronic kidney disease afflicts more than 26 million people in the U.S. alone, according to the National Kidney foundation. Driving the worldwide spread of chronic kidney disease in developed countries are an aging population and the growing problem of obesity.
“The upcoming Rayaldee PDUFA represents the new major catalyst for OPKO,” says Dana Flanders, equity analyst at J.P. Morgan Securities, who rates the stock, currently trading a $11.59 a share, as “overweight.” The analyst notes that OPKO has held labeling discussions with the FDA, and that the company is now researching product pricing, manufacturing preparations and inventory, as well as key hiring of sales representatives for Rayaldee’s launch.
Flanders sees Rayaldee as a “meaningful growth driver” for OPKO and forecasts sales reaching about $500 million by 2025. To demonstrate how big a product Rayaldee could be, that $500 million figure is more than OPKO’s consolidated revenues for all of 2015.
OPKO is on the cusp of “what we expect to be a healthy growth cycle, driven by several potentially promising product launches across its pharma, biologics, and diagnostics businesses,” says Flanders. Additionally, the analyst believes OPKO’s acquisition of Bio-Reference Labs, the third latest clinical laboratory in the U.S., “will support uptake of the company’s diagnostics platform and add a valuable genetics testing franchise (GeneDx).”
Recommended by Forbes
Glad to see you back..look forward to your posts
For sure..my main holdings are RSO and AGNC..and small amounts of CIM and NLY
We agree at last..
JNSH come down to .0025 again VNDM...
Still in 100%
Sounds right to me..The only thing I wonder about is what kind of person buys 888 shares of a stock that trades for a fraction of a penny..guess it takes all kinds...
JNSH..dump it..will be fun to see how deep in the trips it goes..give me a days notice and I will have tiered bids in..to help absorb some..
OPK..Cocrystal Pharma Announces Filing Its Quarterly..
http://finance.yahoo.com/news/cocrystal-pharma-announces-filing-quarterly-221832746.html
RCHN..how about a tweet for RCHN..they had a great quarter..